Elect were invited to review the work of specialists in the arena of medical research to determine whether the project being undertaken qualifies for R & D tax credits.
After detailed discussions with the client we established an entitlement to make a claim under the SME scheme (the company has less than 500 employees, turnover less than €100m, balance sheet less than €86m).
The company has designed, and is developing pioneering technologies that will resurrect anti-microbial therapies made ineffective by increasing microbial resistance. These solutions will impact one of the world’s most significant clinical problems by not only treating antibiotic resistant infections, but also by preventing them in susceptible patients. The technology will make existing antibiotics work effectively again, as well as maintaining the efficacy of newly developed antibiotics. It is applicable to all antibiotic classes, all known resistance mechanisms and all bacteria.
The claim was formed largely from a proportion of staff costs, consumables and contractor costs provided the client with a significant tax credit enabling them to continue their amazing work.